Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALStandard

PLIAGLIS

LIDOCAINE; TETRACAINE

Standard Dose
7%;7%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PLIAGLIS is listed in Drugs@FDA under application 021717 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE; TETRACAINE Form and strength CREAM;TOPICAL - 7%;7% Sponsor CRESCITA THERAP Submission history Latest submission status date: 2018-12-11 00:00:00.

Structured Monograph

Clinical summary

Approval overview PLIAGLIS is listed in Drugs@FDA under application 021717 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LIDOCAINE; TETRACAINE Form and strength CREAM;TOPICAL - 7%;7% Sponsor CRESCITA THERAP Submission history Latest submission status date: 2018-12-11 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.
PLIAGLIS (LIDOCAINE; TETRACAINE) | Drug Monograph | MedicHelpline